Denali Therapeutics Inc (NASDAQ: DNLI) kicked off on Monday, up 7.44% from the previous trading day, before settling in for the closing price of $13.44. Over the past 52 weeks, DNLI has traded in a range of $10.57-$33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -4.46%. While this was happening, its average annual earnings per share was recorded -18.54%. With a float of $125.73 million, this company’s outstanding shares have now reached $145.25 million.
Let’s determine the extent of company efficiency that accounts for 422 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 13.46%, while institutional ownership is 92.48%. The most recent insider transaction that took place on Jul 09 ’25, was worth 7,429,230. In this transaction President and CEO of this company sold 495,282 shares at a rate of $15.00, taking the stock ownership to the 253,071 shares. Before that another transaction happened on Jul 09 ’25, when Company’s Officer proposed sale 495,282 for $14.33, making the entire transaction worth $7,097,391.
Denali Therapeutics Inc (DNLI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -18.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.71% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Take a look at Denali Therapeutics Inc’s (DNLI) current performance indicators. Last quarter, stock had a quick ratio of 9.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.76 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Looking closely at Denali Therapeutics Inc (NASDAQ: DNLI), its last 5-days average volume was 1.88 million, which is a jump from its year-to-date volume of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 41.83%.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 60.47%, which indicates a significant decrease from 62.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.68 in the past 14 days, which was lower than the 0.83 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.19, while its 200-day Moving Average is $18.64.
